Cipla USA Inc., a subsidiary of Cipla Limited, has announced the immediate launch of its generic version of Saxenda (liraglutide injection) in the United States. Approved by the USFDA through partner Orbicular, this move strengthens Cipla’s portfolio in weight management therapies, enhancing affordability and access for patients.
Cipla has taken a decisive step in expanding its U.S. portfolio by introducing the generic equivalent of Saxenda, a liraglutide injection used for chronic weight management. The launch comes after the U.S. Food and Drug Administration (USFDA) granted Abbreviated New Drug Approval (ANDA) to Cipla’s partner Orbicular.
Key Highlights
-
Immediate launch of liraglutide injection, 18 mg/3 mL prefilled pens, designed for single-patient use
-
Strengthens Cipla’s U.S. presence in the fast-growing weight management therapy segment
-
FDA approval ensures safety, efficacy, and quality standards equivalent to Saxenda
-
Addresses rising demand for GLP-1 receptor agonists amid obesity and diabetes concerns
-
Expected to improve affordability and patient access during ongoing shortages of branded therapies
This development positions Cipla as a competitive player in the complex generics space, aligning with global healthcare trends that emphasize cost-effective solutions for chronic conditions. The generic Saxenda launch is not only a commercial milestone but also a strategic move to meet urgent patient needs in obesity management.
Sources: Yahoo Finance, PR Newswire, Pharmacy Times